New drug combo shows promise against tough cancers

NCT ID NCT04349267

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right dose. Researchers also looked at whether tumors shrank. The study is complete, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986315 (an experimental immunotherapy drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors like head and neck, lung, or kidney cancer.
What could go wrong: This is an early-phase trial with only 44 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood kidney cell carcinoma head and neck squamous cell carcinoma non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Local Institution

Mexico City, Mexico City, 06100, Mexico
Local Institution - 0001

Germantown, Tennessee, 38138, United States
Local Institution - 0004

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0005

Montreal, Quebec, H2X 3E4, Canada
Local Institution - 0011

Vancouver, British Columbia, V5Z 4E6, Canada
Local Institution - 0013

Ottawa, K1H 8L6, Canada
Local Institution - 0014

Edmonton, Alberta, T6X 1E8, Canada
Local Institution - 0028

Sioux Falls, South Dakota, 57104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.